Brief: Newron Announces Positive Top-Line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide In Schizophrenia Patients
30/04/2024 12:12
April 30 (Reuters) - Newron Pharmaceuticals SpA
NWRN.S :
* NEWRON ANNOUNCES POSITIVE TOP-LINE RESULTS FROM
POTENTIALLY
PIVOTAL PHASE II/III STUDY 008A WITH EVENAMIDE IN SCHIZOPHRENIA
PATIENTS
* NEWRON PHARMACEUTICALS SPA: PRIMARY ENDPOINT AND KEY
SECONDARY
ENDPOINT OF STUDY MET; DRUG WAS WELL TOLERATED, WITH NO SAFETY
CONCERNS IDENTIFIED
Source text for Eikon: ID:nBw4WLcSsa
Further company coverage: NWRN.S
(Reuters.Briefs@thomsonreuters.com)
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study